A Study of the Safety of REN001 in Patients With McArdle Disease

Phase 1

Completed

• Conditions: McArdle Disease
• Interventions: Drug: REN001

• Registration Number: NCT04226274
• Lead Sponsor: Reneo Pharma Ltd

Brief Summary

The purpose of this study is to assess REN001 safety in subjects with McArdle Disease

Detailed Description

Not available

Study Timeline

• Study Start: 2019-12-10
• Study First Submitted: 2020-01-09
• Study First Submitted QC: 2020-01-10
• Study First Posted: 2020-01-13
• Primary Completion: 2021-10-11
• Study Completion: 2021-10-11
• Status Verified: 2022-01
• Last Update Submitted: 2022-01-11
• Last Update Posted: 2022-01-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 19

Inclusion Criteria

• Subjects must give written, signed and dated informed consent
• Confirmed diagnosis of McArdle Disease
• Subjects must be able to remain on stable medication through the study and specifically must not commence or have changes to agents that affect metabolism such as medication for diabetes
• Follow a stable dietary regimen as documented by a 3-day dietary record obtained during the screening period.

Exclusion Criteria

• Documented history of ongoing rhabdomyolysis
• Evidence of acute crisis from their underlying disease
• Currently following or planning to start a ketogenic diet
• Treatment with an investigational drug within 1 month or within 5 half-lives, whichever is longer
• Have been hospitalized within the 3 months prior to screening for any major medical condition
• Severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the Investigator in discussion with the Medical Monitor, would make the subject inappropriate for entry into this study
• Pregnant or nursing females

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
REN001	REN001	Oral

Primary Outcome Measures

Name	Time	Method
Adverse Events	up to Week 12	Number of participants with Adverse Events (AEs) as a measure of safety and tolerability

Trial Locations

Locations (2)

Instituto de Investigación Hospital 12 de Octubre; 🇪🇸 Madrid, Spain

National Hospital for Neurology and Neurosurgery, Queens Square; 🇬🇧 London, United Kingdom